Amagma Therapeutics announces strategic partnership with Innovent Biologics

By The Science Advisory Board staff writers

January 19, 2022 -- Amagma Therapeutics has entered into a license option agreement with Innovent Biologics for up to three enzyme-specific inhibitors derived from Amagma's proprietary Seizmic platform.

The Seizmic platform leverages a structure-based approach to identify highly selective antibodies that inhibit dysregulated proteases and other enzymes of interest, Amagma said. The collaboration will allow Innovent to access novel molecules for inflammatory disorders with little to no existing treatment options.

Under the agreement, Innovent will be responsible for the manufacture of the three programs through a phase II study. If Innovent exercises its option, it will also be responsible for R&D and commercialization of each program in China. Amagma will continue to be responsible for global R&D prior to option exercise and ex-China R&D and commercialization thereafter, according to the company.

Amagma is eligible to receive development, approval, and commercial milestones if Innovent exercises the options. Amagma may also receive royalties on net sales of any commercial products in the territory.

Financial details of the agreement were not disclosed.

Bolt Bio, Innovent collaborate on oncology agents
Bolt Biotherapeutics and Innovent Biologics are collaborating to develop three anticancer drug candidates based on Bolt's therapeutic immune-stimulating...
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...
Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter